Nafithromycin launch: Habil Khorakiwala on 3 things in the pipeline that can cause a re-rating for Wockhardt
Habil Khorakiwala says: “We have earlier signed an agreement on a profit-sharing basis for contract manufacturing with Serum Institute to make vaccines in our UK facility. This is a long 15-year agreement and we have earmarked capacity for 150 million doses for them. We are also in discussion with a global vaccine company for contract manufacturing opportunities.”
United States Uttar Pradesh United Kingdom Wockhardt Group Offering College Indian School Of Business
Source: indiatimes.com